HAEK.DE(HAEK.DE)
HAEK.DE
$21.40—Stale · unknown old
XETRA • Last print unknown ago
$21.40—Stale · unknown old
Haemato AG is a German pharmaceutical company specializing in the distribution of specialty and generic drugs, particularly in oncology and hematology. The company operates primarily in the European market and differentiates itself through a focused portfolio of niche products and strong relationships with healthcare providers.
Haemato AG generates revenue through the sale of specialty and generic drugs, leveraging its established distribution network and partnerships with healthcare providers. The company benefits from a low debt level (Debt/Equity of 0.04), allowing for flexibility in pricing strategies and investment in niche markets.
Changes in regulatory approvals for specialty drugs
Market demand for oncology and hematology products
Pricing pressures from competitors
Partnerships with healthcare providers
Regulatory changes affecting drug approvals and pricing
Technological disruption in drug development and distribution
Increased competition from generic drug manufacturers
Potential market entry of larger pharmaceutical companies
Low operating cash flow could limit investment in growth opportunities
Negative ROA indicates inefficiencies in asset utilization
moderate - The company's performance is somewhat linked to healthcare spending, which can be influenced by GDP growth and consumer spending.
Interest rates can affect Haemato's financing costs, although with low debt levels, the impact may be minimal. Higher rates could also dampen consumer spending on healthcare.
minimal - The company's low debt levels reduce its sensitivity to credit conditions.
value - Investors may be attracted to the stock due to its low valuation metrics, such as a Price/Sales ratio of 0.4x.
moderate - The stock has shown a historical volatility consistent with the healthcare sector, but recent performance has been more stable.